CONVERGE Post-Approval Study (PAS)

Study Summary

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Conditions

Chronic Atrial Fibrillation

Interventions / Drugs

Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment53 participants

Primary Completion—

Lead SponsorAtriCure, Inc.

Data Retrieved2026-04-11 02:55:07.545216+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.